RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2021 -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and Gilbert...
Chimerix Awarded BARDA Contract for Advanced Development of CMX001 as Medical Countermeasure Against Smallpox
News | 02. 16. 2011
Chimerix
Chimerix, Inc., a pharmaceutical company developing orally available antiviral therapeutics, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Chimerix’s broad spectrum antiviral drug candidate, CMX001, as a medical countermeasure in the event of a smallpox release.
